Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial

🏆 Top 20📊 OpenAlex

Most Cited Paper

in Heart Failure Treatment and Management

18 Months Post-Publication

Class of 2026

“Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial”

AuthorsRichard E Pratley et al.

Richard E. Pratley

JournalJournal of the American College of Cardiology

AdventHealth Translational Research Institute

Citations86

DOI10.1016/j.jacc.2024.08.004

A research intelligence initiative by Pepkio

pri.pepkio.com/top-papers/heart-failure-treatment-and-management/2026/

Topics

Semaglutide · Type 2 diabetes · Chronic Kidney Disease · Heart failure · Cardiovascular death · GLP-1 receptor agonist · FLOW trial · Renal dysfunction · Kidney replacement therapy · Renal composite endpoint · Randomized controlled trial · Placebo-controlled trial · Once-weekly dosing · Heart failure hospitalization · Urgent heart failure visit · Diuretic Therapy · Vasoactive therapy · New York Heart Association functional class · Heart failure with reduced ejection fraction · Time-to-event analysis · Hazard ratio · Secondary analysis · Cardiovascular risk reduction · Adjudication committee · Renal dysfunction · Diabetic kidney disease · Composite Endpoint · High-risk cardiometabolic population · Renal outcomes · GLP-1 receptor agonist cardioprotection

Share on X

Cite this ranking

Pepkio Research Index (PRI). Topics and Trends in Most Cited Heart Failure Treatment and Management Papers, Class of 2026. https://pri.pepkio.com/top-papers/heart-failure-treatment-and-management/2026. Accessed 2026-07-13.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459